Related Experiment Video
Updated: Apr 2, 2026

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
Published on: October 5, 2015
Role of Tumor Necrosis Factor in Tuberculosis
Fedor D Kireev1,2, Julia A Lopatnikova1,2, Alina A Alshevskaya2
1Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology" (RIFCI), 630099 Novosibirsk, Russia.
Tumor necrosis factor (TNF) plays a complex role in tuberculosis (TB), aiding infection control but also causing damage. TNF inhibitors vary in risk for TB reactivation, with antibody-based drugs posing a higher threat.
Area of Science:
- Immunology
- Infectious Diseases
- Molecular Biology
Background:
- Tumor necrosis factor (TNF) is a critical cytokine in host defense against Mycobacterium tuberculosis.
- TNF exhibits a dual role, essential for controlling latent infection but also implicated in immunopathology and tissue damage.
Purpose of the Study:
- To systematically review the molecular and cellular mechanisms of TNF action in tuberculosis (TB) pathogenesis.
- To analyze the balance between protective and pathological immune responses driven by TNF.
- To evaluate the impact of anti-TNF therapies on TB risk and host defense.
Main Methods:
- Systematic analysis of over 300 peer-reviewed studies (1980-2024) on TNF in TB.
- Review of TNF receptor signaling pathways and immune modulation.
- Integration of knowledge using schematic representations of TNF-driven immune dynamics.
Main Results:
- Different TNF inhibitors possess varying capacities to disrupt host defense mechanisms against TB.
- Monoclonal antibody TNF inhibitors are associated with a higher risk of TB reactivation compared to receptor-based agents.
- TNF influences granuloma stability and intracellular bacterial control.
Conclusions:
- Understanding TNF's pleiotropic functions in TB pathogenesis is vital for safe immunomodulatory strategies.
- Optimizing clinical management of patients at risk for latent TB reactivation requires careful consideration of TNF-targeting therapies.
- Differentiated risk profiles of TNF inhibitors necessitate tailored clinical approaches.
More Related Videos
10:04Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
09:34An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Related Concept Videos
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF